glp 1 agonists in development Another milestone the evolution of GLP-1-based diabetes therapies GLP-1 receptor agonists | How
Description
The European Medicines Agency has issued a positive recommendation on the same indication
Here's what doctors have to say.
Evidence-based guidance on safety, monitoring, and when to discuss treatment with your healthcare team.
GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure
Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of ...
